Selcia and Gilead Sciences Extend Liver Disease Drug Discovery Collaboration

Selcia Limited, a leading contract research organisation, announced a drug discovery collaboration agreement with Gilead Sciences, Inc. Building on an established partnership following significant progress made to date, Selcia’s chemists and biologists will continue to provide integrated drug discovery services to support Gilead’s liver disease research programmes. Dr. William Lee, Senior Vice President, Research at Gilead Sciences, commented: “We are pleased to announce the continued research collaboration with Selcia in this very important therapeutic area for Gilead. Scientists from both companies have interacted well together and have made successful progress against some difficult targets. We are looking forward to the collaboration delivering candidates for clinical studies in the foreseeable future”. Commenting on the announcement, Selcia’s Managing Director, Dr. Hans Fliri said: “We are delighted to build on our strong collaborative relationship with Gilead in this challenging research area and important therapeutic indication. This represents a significant step forward in the development of Selcia’s Discovery services and further cements our position as a strategic and trusted partner for integrated drug discovery. We look forward to continuing to support Gilead in their search for new drugs to treat liver diseases and in fulfilling their longer term objectives”.

About Selcia

Selcia Limited is a privately held contract research organisation with two operating divisions, Selcia Discovery and Selcia Radiolabelling, operating from a modern facility in Ongar, Essex, UK.

Selcia Discovery provides integrated drug discovery services to pharmaceutical and biotechnology industries; these services include in vitro biology, screening, fragment screening, medicinal, organic and analytical chemistry, and in vitro ADME/PK evaluation as well as in vivo PK (with a strategic partner). Selcia’s scientists act as integrated project teams within the customer group striving to produce viable drug candidates against its partners’ biological targets. Selcia’s expertise in capillary electrophoresis (CE) offers clients the benefits of a versatile and proven technology applied to drug discovery screening on a wide variety of targets. Its proprietary fragment screening service, CEfrag™ is a powerful application of the technique at the outset of a drug discovery programme.

About Gilead

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company’s mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia.

For more information on Gilead Sciences, please visit

For more information, please contact:

Selcia Limited:
Dr Hans Fliri, Managing Director
T: +44 (0)1277 367000

Key Media Contact:
Oliver Woodman-Smith
Tel: +44 (0)117 9739224